Link Biologics completes IND-enabling preclinical programme for LB001, a first-in-class novel therapy for dry eye disease

Completion of key IND-enabling activities represents a major development milestone for LB001 IND submission remains on track for Q1 2027, followed by initiation of a Phase 1/2 clinical study Manufacturing scale-up completed, providing supply for planned clinical studies London, UK – 5 November 2026 – Link Biologics (“Link” or “the Company”), the biotech developing first-in-class […]

Asgard Therapeutics announces publication in Immunity demonstrating induction of cancer-fighting tertiary lymphoid structures across seven tumor types – and will present new AT-108 biomarker data at SITC 2026

Study in Immunity highlights Asgard’s ability to generate potent immunogenic tertiary lymphoid structures (imgTLSs) solely by reprogramming tumor cells into antigen-presenting conventional type 1 dendritic cells (cDC1s) directly within tumors. imgTLS formation seen across seven different tumor types from inflamed to non-T-cell inflamed and in immunosuppressed tumor microenvironments, demonstrating tumor-agnostic activity. Tumor-to-dendritic cell reprogramming led […]

AC Immune Third Quarter 2026 Financial and Corporate Update

Positive clinical and regulatory progress achieved across wholly-owned pipeline ACI-7104 received FDA Fast Track designation, Investigational New Drug (IND) clearance, and reported positive Part 1 week-100 results from the Phase 2 VacSYn trial in Parkinson’s disease Positive interim safety and tolerability results from the Phase 1 trial of NLRP3 inhibitor ACI-19764 in healthy volunteers Lead […]

Hansa Biopharma to participate in BIO-Europe 2026

Lund, Sweden, November 4. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a panel titled “Immunology under the microscope: New frontiers” at BIO-Europe 2026, on Tuesday 10 November, at 14:00 CET, at the Koelnmesse, in Cologne, Germany. Read more…

New research initiative will utilise AI to optimise Nordic energy grid capacity, improve resilience and prepare for future needs

A new Nordic research initiative will develop artificial intelligence-based solutions to help power grid operators optimise the use of existing grid infrastructure, handle growing uncertainty, and keep power grids resilient as electricity demand increases. Read more…

© Optimum Strategic Communications.